Summary
- Merck agreed to acquire Tilos Therapeutics for $773 million, which opens up the possibility of using anti-LAP antibodies to target cancer, fibrosis, and autoimmune diseases.
- The ability for anti-LAP antibodies to disrupt the microtumor environment could make it viable to be combined with the likes of Keytruda to improve clinical outcomes in patients with cancer.
- Merck recently gained two new FDA approvals under its belt, which should help keep Keytruda on top in the checkpoint inhibitor space.
- Keytruda generated more than $7 billion in sales in 2018 and then saw an impressive Q1 2019 with $2.26 billion in sales alone.
- Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our model portfolio. Start your free trial today ยป
Merck (MRK) announced that it had entered into an agreement to acquire Tilos Therapeutics. This is a good deal for Merck because it will give it an opportunity to test its drug Keytruda in combination with Tilos' anti-LAP antibodies to treat patients with cancer. The promise of this early stage program is strong because such anti-LAP antibodies can also be used for fibrosis and autoimmune diseases. This opens up the door for many other potential indications to go after with this type of technology.
